|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.760 USD | -2.22% |
|
-2.76% | -45.34% |
| 06-29 | Gain Therapeutics Gets FDA Approval to Start Phase 2 Study of Parkinson's Drug | DJ |
| 06-29 | Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease | MT |
| Market Cap | 75.07M 65.84M 60.98M 56.11M 106M 7.19B 108M 727M 285M 3.53B 282M 276M 12.19B | P/E 2026 * |
-3.15x | P/E 2027 * | -2.37x |
|---|---|---|---|---|---|
| Enterprise Value | 75.07M 65.84M 60.98M 56.11M 106M 7.19B 108M 727M 285M 3.53B 282M 276M 12.19B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
97.71% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -2.22% | ||
| 1 week | -2.76% | ||
| Current month | -13.30% | ||
| 1 month | +4.76% | ||
| 3 months | -5.88% | ||
| 6 months | -21.08% | ||
| Current year | -45.34% |
| 1 week | 1.74 |  | 1.87 |
| 1 month | 1.68 | | 2.24 |
| Current year | 1.53 | | 3.29 |
| 1 year | 1.41 | | 4.34 |
| 3 years | 0.89 | | 5.33 |
| 5 years | 0.89 | | 9.75 |
| 10 years | 0.89 | | 17.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gene Mack
CEO | Chief Executive Officer | 52 | 2024-06-24 |
| Director of Finance/CFO | 37 | 2025-01-05 | |
Jonas Hannestad
CTO | Chief Tech/Sci/R&D Officer | - | 2024-03-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Khalid Islam
CHM | Chairman | 69 | 2016-12-31 |
Jeffrey Riley
BRD | Director/Board Member | 63 | 2019-04-30 |
Dov Goldstein
BRD | Director/Board Member | 58 | 2020-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03-23 | Free | Chief Financial Officer | 50,000 | 0.1300% | ||
| 03-23 | Free | Chief Executive Officer | 200,000 | 0.5200% | ||
| 25-06-23 | Free | Director | 15,000 | 0.0507% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.22% | -2.76% | +1.73% | -60.89% | 75.07M | |
| -0.65% | +1.50% | +3.26% | +7.09% | 50.61B | |
| -1.57% | -3.18% | +383.82% | +593.37% | 39.11B | |
| -0.14% | +0.77% | +27.49% | -5.50% | 34.64B | |
| +1.76% | -1.78% | +21.44% | +53.38% | 33.79B | |
| -0.06% | -0.45% | +2.94% | +28.70% | 26.89B | |
| -1.93% | -1.01% | - | - | 16.47B | |
| -1.49% | -6.18% | +63.89% | +120.53% | 15.14B | |
| -0.89% | -0.15% | +14.39% | +16.64% | 13.85B | |
| -0.97% | -2.83% | +10.35% | -33.29% | 12.72B | |
| Average | -0.83% | -1.61% | +58.81% | +80.00% | 24.33B | |
| Weighted average by Cap. | -0.50% | -1.08% | +80.37% | +121.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -24.41M -21.41M -19.83M -18.24M -34.5M -2.34B -35.18M -236M -92.68M -1.15B -91.65M -89.64M -3.96B | -36.06M -31.63M -29.29M -26.95M -50.98M -3.45B -51.97M -349M -137M -1.69B -135M -132M -5.85B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-13 | US$1.760 | -2.22% | 997,398 |
| 26-07-10 | US$1.800 | -1.10% | 610,322 |
| 26-07-09 | US$1.820 | +1.68% | 589,393 |
| 26-07-08 | US$1.790 | -1.10% | 591,154 |
| 26-07-07 | US$1.810 | 0.00% | 743,472 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GANX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
